Samsung Biologics secured its largest-ever manufacturing contract, valued at 1.7 trillion won ($1.24 billion), with an undisclosed Asian pharmaceutical company. The 13-year deal runs through 2037 and pushes the company’s annual order intake above 4 trillion won for the first time.
The contract marks the South Korean manufacturer’s second major deal in three months, following a 1.46 trillion won agreement with a U.S. drugmaker in July. The company’s order book has now reached 4.36 trillion won this year, surpassing 2023’s total by 20%.
Samsung Biologics is expanding its manufacturing footprint with a fifth plant, scheduled for completion in April 2025. The facility will add 180,000 liters of capacity, bringing the total to 784,000 liters.
The contract manufacturer has secured 326 regulatory approvals globally, including 39 from the U.S. FDA and 34 from Europe’s EMA. The company claims a 99% batch success rate in production.
While Samsung Biologics counts 17 of the top 20 pharmaceutical companies as clients, the company faces increasing competition in the global biologics manufacturing space as demand for production capacity continues to grow.
